United Therapeutics (UTHR) Price to Sales (2009 - 2026)

United Therapeutics has disclosed Price to Sales across 18 years of filings, most recently posting 29.52 for Q2 2026.

• In Q2 2026, Price to Sales rose 81.45% year-over-year to 29.52; the TTM figure through Jun 2026 stood at 7.33 (up 73.65% YoY), while the FY2025 annual figure was 6.68, up 21.54% from the prior year.
• Price to Sales came in at 29.52 for Q2 2026 at United Therapeutics, down from 31.99 in the prior quarter.
• In the past five years, Price to Sales ranged from a high of 31.99 in Q1 2026 to a low of 14.98 in Q1 2024.
• Average Price to Sales over 5 years is 21.09, with a median of 20.21 recorded in 2024.
• Year-over-year, Price to Sales sank 35.39% in 2023 and jumped 82.87% in 2026.
• Over 5 years, Price to Sales stood at 26.04 in 2022, then sank by 35.39% to 16.83 in 2023, then grew by 27.74% to 21.5 in 2024, then rose by 25.2% to 26.91 in 2025, then rose by 9.7% to 29.52 in 2026.
• Per Business Quant data, the three most recent Price to Sales figures were 29.52 in Q2 2026, 31.99 in Q1 2026, and 26.91 in Q4 2025.